X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (761) 761
Publication (30) 30
Conference Proceeding (8) 8
Book Review (5) 5
Patent (3) 3
Reference (2) 2
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (342) 342
male (200) 200
index medicus (199) 199
female (194) 194
middle aged (186) 186
aged (175) 175
hematology (173) 173
adult (152) 152
oncology (152) 152
chronic lymphocytic leukemia (99) 99
leukemia, lymphocytic, chronic, b-cell - drug therapy (91) 91
rituximab (91) 91
aged, 80 and over (85) 85
cladribine (81) 81
chronic lymphocytic-leukemia (79) 79
treatment outcome (78) 78
antineoplastic combined chemotherapy protocols - therapeutic use (76) 76
fludarabine (73) 73
antineoplastic agents - therapeutic use (71) 71
apoptosis (61) 61
cancer (61) 61
pharmacology & pharmacy (53) 53
prognosis (51) 51
cll (50) 50
chemotherapy (47) 47
leukemia, lymphocytic, chronic, b-cell - pathology (47) 47
cyclophosphamide (44) 44
leukemia (44) 44
therapy (44) 44
animals (43) 43
cladribine - administration & dosage (43) 43
antibodies, monoclonal - therapeutic use (41) 41
survival (41) 41
multiple myeloma (39) 39
non-hodgkins-lymphoma (39) 39
antineoplastic agents - pharmacology (38) 38
disease-free survival (37) 37
monoclonal antibodies (37) 37
acute myeloid leukemia (34) 34
lymphoma (34) 34
purine nucleoside analogs (33) 33
immunology (32) 32
abridged index medicus (31) 31
alemtuzumab (30) 30
care and treatment (30) 30
vidarabine - analogs & derivatives (30) 30
chlorambucil (28) 28
cyclophosphamide - administration & dosage (28) 28
diagnosis (28) 28
antineoplastic combined chemotherapy protocols - adverse effects (27) 27
hematology, oncology and palliative medicine (27) 27
leukemia, lymphocytic, chronic, b-cell - mortality (27) 27
expression (26) 26
in-vitro (26) 26
antineoplastic combined chemotherapy protocols - administration & dosage (25) 25
biochemistry & molecular biology (25) 25
bortezomib (25) 25
case-control studies (25) 25
recurrence (25) 25
research (25) 25
survival analysis (25) 25
angiogenesis (24) 24
clinical trials as topic (24) 24
leukemia, lymphocytic, chronic, b-cell - genetics (24) 24
trial (24) 24
adolescent (23) 23
cladribine - therapeutic use (23) 23
ofatumumab (23) 23
survival rate (23) 23
antineoplastic agents - adverse effects (22) 22
cell biology (22) 22
ibrutinib (22) 22
multicenter (22) 22
neoplasm staging (22) 22
2-chlorodeoxyadenosine (21) 21
follow-up studies (21) 21
lymphomas (21) 21
proteins (21) 21
remission induction (21) 21
treatment (21) 21
acute myeloid-leukemia (20) 20
apoptosis - drug effects (20) 20
b-cll (20) 20
phase-ii trial (20) 20
stem cell transplantation (20) 20
young adult (20) 20
2-cda (19) 19
antibodies, monoclonal - administration & dosage (19) 19
antibodies, monoclonal - adverse effects (19) 19
antineoplastic agents - administration & dosage (19) 19
open-label (19) 19
term-follow-up (19) 19
cladribine - adverse effects (18) 18
drug resistance, neoplasm (18) 18
leukemia, lymphocytic, chronic, b-cell - immunology (18) 18
minimal residual disease (18) 18
mutation (18) 18
nucleoside analogs (18) 18
patients (18) 18
pentostatin (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Lancet. Haematology, 12/2018
Journal Article
International Journal of Fatigue, ISSN 0142-1123, 08/2018, Volume 113, p. 246
This paper presents the problems relating to the determination of the material constants and their assessment. The study demonstrated that the scatter of the... 
Fatigue life | Parameters | Measures of variability | Notches | Dependence | Materials fatigue | Fatigue failure
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1873 - 1883
Summary Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based... 
Internal Medicine | BENDAMUSTINE | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CLL | CYCLOPHOSPHAMIDE | CHEMOIMMUNOTHERAPY | RITUXIMAB | MONOCLONAL-ANTIBODIES | ELDERLY-PATIENTS | FLUDARABINE | HUMAN CD20 | Age Distribution | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Chlorambucil - adverse effects | Prospective Studies | Chlorambucil - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents, Alkylating - administration & dosage | Aged, 80 and over | Adult | Female | Chlorambucil - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Agents, Alkylating - therapeutic use | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sex Distribution | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antineoplastic Agents, Alkylating - adverse effects | Chlorambucil | Medical colleges | Hospitals | Comorbidity | United Kingdom | Product development | India | Medical research | Flow cytometry | Immunoglobulins | Medical imaging | Laboratories | Cytotoxicity | Infections | Ovarian cancer | Bone marrow | Drug dosages | Age | Binding sites | Geriatrics | Neutropenia
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 5, pp. 431 - 440
Journal Article
Recent Patents on Anti-Cancer Drug Discovery, ISSN 1574-8928, 04/2016, Volume 11, Issue 2, pp. 139 - 140
Journal Article
International Journal of Fatigue, ISSN 0142-1123, 08/2018, Volume 113, pp. 246 - 252
This paper presents the problems relating to the determination of the material constants and their assessment. The study demonstrated that the scatter of the... 
Fatigue life | Fatigue notch factor | Critical length | Number of cycles to failure | CRITICAL DISTANCES | ENERGY MODELS | MATERIALS SCIENCE, MULTIDISCIPLINARY | ALGORITHM | COMPONENTS | CONSTANT | STRESS INTENSITY | AMPLITUDE | SCATTER | ENGINEERING, MECHANICAL | THRESHOLD | LIFE ESTIMATION | Fatigue testing machines | Fatigue | Materials
Journal Article
Future Oncology, ISSN 1479-6694, 10/2015, Volume 11, Issue 20, pp. 2807 - 2818
Mantle cell lymphoma (MCL) is a hematological malignancy with unfavorable prognosis. Bortezomib, a potent, selective and reversible inhibitor of the 26S... 
Phase III | safety | stem cell transplantation | immunochemotherapy | mantle cell lymphoma | bortezomib | novel agents | SURVIVAL | 1ST-LINE TREATMENT | APOPTOSIS | MULTICENTER | PLUS RITUXIMAB | NATIONAL-CANCER-INSTITUTE | PHASE-II | INDOLENT | CHEMOTHERAPY | ONCOLOGY | PROTEASOME INHIBITOR BORTEZOMIB
Journal Article
Blood, ISSN 0006-4971, 12/2013, Volume 122, Issue 24, pp. 3854 - 3855
In this issue of Blood, Abrisqueta and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance therapy in chronic... 
TRIAL | CONSOLIDATION | CYCLOPHOSPHAMIDE | RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | PHASE-3 | HEMATOLOGY | FLUDARABINE | Female | Male | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Humans
Journal Article
Future Oncology, ISSN 1479-6694, 01/2013, Volume 9, Issue 1, pp. 69 - 91
Monoclonal antibodies (mAbs) - rituximab, ofatumumab and alemtuzumab - have been approved for use in the therapy of chronic lymphocytic leukemia (CLL).... 
CD20 | CD40 | alemtuzumab | TRU-016 | ofatumumab | CD37 | moxetumomab pasudotox | lucatumumab | inotuzumab ozogamicin | obinutuzumab | rituximab | DENILEUKIN DIFTITOX | HUMANIZED ANTI-CD20 ANTIBODY | CMC-544 INOTUZUMAB OZOGAMICIN | ANTITUMOR-ACTIVITY | B-CELL LYMPHOMA | ONCOLOGY | FUSION PROTEIN | NON-HODGKINS-LYMPHOMA | POTENT IN-VITRO | 1ST-LINE THERAPY | PHASE-I | Index Medicus | Antitumor activity
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 3, pp. 297 - 311
Journal Article
Drugs in R&D, ISSN 1174-5886, 6/2019, Volume 19, Issue 2, pp. 73 - 92
Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Kinases | Lymphomas | Multiple myeloma | Review
Journal Article